Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 12, 1996, Pages 927-932

  Simondon, F ^a,b   Yam, A ^a   Gagnepain, J Y ^a   Wassilak, S ^c   Danve, B ^d   Cadoz, M ^d  

^a U Rech Sur Les Maladies I   (Senegal)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Pasteur Merieux Serums et Vaccins   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; POLIOMYELITIS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENEGAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BORDETELLA PERTUSSIS; CLOSTRIDIUM TETANI; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTININS; HUMANS; INFANT; MALE; PERTUSSIS TOXIN; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; SENEGAL; TETANUS; VACCINATION; VACCINES, COMBINED; VACCINES, SYNTHETIC; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0030466833     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01690510     Document Type: Article

References (18)

1. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB: A placebo controlled trial of a pertussis toxoid vaccine. New England Journal of Medicine 1995, 333: 1045-1050.
2. Greco D, Salmoso S, Mastrantonio P, Giuliano M, Tozzi A, Anemona A, Ciofi Degli Atti M, Giammanco A, Panei P, Blackwelder W, Klein D, Wassilak S, and the Progetto Pertosse Working Group: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine 1996, 334: 341-348.
3. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine 1996, 334: 349-355.
4. Schmitt HJ, von Konig CHW, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, Clemens R: Efficacy of acellular pertussis vaccine in early childhood after household exposure. Journal of the American Medical Association 1996, 275: 37-41.
5. Wright PF: Pertussis in developing countries: definition of the problem and prospects for control. Reviews of Infectious Diseases 1991, 13, Supplement 6: 528-534.
6. Mulholland K: Measles and pertussis in developing countries with good vaccine coverage. Lancet 1995, 345: 305-307.
7. Christy C, Pichichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, Englund JA, Edwards KM, Steinhoff MC: Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995, 96, Supplement 3: 584-587.
8. Aaby P, Samb B, Simondon F, Whittle H, Coll Seek AM, Knudsen K, Bennett J, Markowitz L, Rhodes P: Child mortality after high-titre measles vaccines in Senegal: the complete data set. Lancet 1991, 338: 1518.
9. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seek AM, Bennett J, Whittle H: Divergent mortality for male and female recipients of low-titre and high-titre measles vaccines in rural Senegal. American Journal of Epidemiology 1993, 138: 746-755.
10. Hewlett EL, Sauer KT, Myers GA, Cowell JL, Guerrant RL: Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infection and Immunology 1983, 40: 1198-1203.
11. Granstrom M, Granstrom G, Gillenius P, Askelof P: Neutralization antibodies to pertussis toxin in whooping cough. Journal of Infectious Diseases 1985, 151: 646-649.
12. Manclark CR, Cowell JL: Pertussis. In: Germanier R (ed): Bacterial vaccines. Academic Press, New York, 1984, p. 69-106.
13. Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, Dupont W, Hager CC, Whright PJ: Evaluation of a new highly purified vaccine in infants and children. Journal of Infectious Diseases 1989, 160: 832-837.
14. Fleming DS, Greenberg L, Beith EM: The use of combined antigens in the immunization of infants. Canadian Medical Association Journal 1948, 59: 101-105.
15. Tarzaali A, Viens P, Quevillon M: Inhibition of the immune response to whooping cough and tetanus vaccines by malaria infection, and the effect of pertussis adjuvant. American Journal of Tropical Medicine and Hygiene 1977, 26: 520-524.
16. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA: Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 1995, 96, Supplement 3: 548-557.
17. Steinhoff MC, Reed GF, Decker MD, Edwards KM, Englund JA, Pichichero ME, Rennels MB, Anderson EL, Deloria MA, Meade BD: A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995, 96, Supplement 3: 567-570.
18. Edwards KM, Decker MD, Halsey NA, Koblin BA, Towsend T, Auerbach B, Karzon DT: Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991, 88: 1019-1023.